about
GABA and Glutamate Transporters in BrainAdjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304Neurosteroid replacement therapy for catamenial epilepsyNew molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channelsLong-range and short-range tumor-stroma networks synergistically contribute to tumor-associated epilepsy.Treatment of Generalized Convulsive Status Epilepticus in Pediatric PatientsPerampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptabilityRegulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsyThe riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant.Homeostasis or channelopathy? Acquired cell type-specific ion channel changes in temporal lobe epilepsy and their antiepileptic potentialEpilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsyMechanisms of Action of Antiseizure Drugs and the Ketogenic DietAnti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.Deletion of the Kv2.1 delayed rectifier potassium channel leads to neuronal and behavioral hyperexcitability.Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disordersDV21 decreases excitability of cortical pyramidal neurons and acts in epilepsy.Anticonvulsant activity of 2,4(1H)-diarylimidazoles in mice and rats acute seizure models.Amygdalocortical circuitry in schizophrenia: from circuits to molecules.The Concise Guide to PHARMACOLOGY 2013/14: ion channelsThe ketogenic diet in a pill: is this possible?The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy.Genetic regulation of gene expression in the epileptic human hippocampus.Perinatal hypoxia: different effects of the inhibitors of GABA transporters GAT1 and GAT3 on the initial velocity of [3H]GABA uptake by cortical, hippocampal, and thalamic nerve terminals.Headache-type adverse effects of NO donors: vasodilation and beyondFrontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.Metabotropic glutamate receptors in the thalamocortical network: strategic targets for the treatment of absence epilepsy.The role of gap junction channels during physiologic and pathologic conditions of the human central nervous systemTargeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy.Seizure control by decanoic acid through direct AMPA receptor inhibitionEmerging drugs for epilepsy.Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets?Use of antiepileptic drugs for hyperkinetic movement disorders.GABAB receptors in maintenance of neocortical circuit function.Isolated seizures in rats do not cause neuronal injury.The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.Combined treatment with diazepam and allopregnanolone reverses tetramethylenedisulfotetramine (TETS)-induced calcium dysregulation in cultured neurons and protects TETS-intoxicated mice against lethal seizures.Synthesis and anticonvulsant activity of new N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide derivatives.
P2860
Q21090476-0267ABAF-04D9-47F1-8470-D8E53934AC4CQ24621743-95B48304-565F-4CAC-85A8-7607E9E616BCQ24643667-ADC3F49A-DA08-4A34-862F-86629A6F61A4Q24654230-DB6EB1E0-33D9-4E6E-B639-E6DEB367107FQ26766290-30CEEA19-E814-4B87-B076-B2FB9586FA27Q26783899-404F0EBF-0F2D-46FD-A6DF-4CAC5A50F2B4Q26796447-92CFDB69-82EA-4C98-9AC6-34BD57A7D825Q26859135-F58B070E-AEA0-4D7C-BA3D-F89FC89BCF63Q27339255-966D86D6-664E-40F7-9EBF-A5318EB29371Q28080655-4F66BD4C-942D-4D2C-B547-C9527A780959Q28259250-F712CAE0-AF22-45E4-BDB3-3D4E4EBC462AQ28272457-FED41E93-ABCB-46BB-9031-CBBA91BC67AAQ28281249-2B65C3D0-806C-4A3D-A4C0-A8319F3202EBQ28510330-7AED2ACA-F6AE-4D90-8BAF-97F458C89B6EQ28833549-2803B7BC-D65A-460E-A51C-2B23C46D9834Q29994691-7BC16E65-7B48-4B96-A0E6-0AD95F632ACFQ30429729-AAB0A1A1-6B21-4B1A-99CB-F7D23AFE493CQ30475524-48258F66-8BA3-4B3D-96D2-2E47A3A2C125Q30486735-5C2483AF-8524-49D9-A283-2FA3540F2EB6Q33346385-25C47D33-3619-4291-A49A-C5A460E308BDQ33615756-62D29BDE-0E8D-4BAD-9B11-46B0B55C0593Q33621804-86E4B7F2-5ADB-4841-AA0A-5FB36CBC20DAQ33622547-1504FA20-577B-4D47-AD7B-EE7B8F6094B9Q33725429-8BE03ADE-0DA6-4E9B-A5C6-B274A8AE7C29Q33812736-76A3969F-CDD6-44A6-A49A-927F147D8EA1Q33972726-50F1F020-FB88-457D-AD8F-A7797F7925B7Q34132754-C7B0FE9A-49AC-419F-B7FF-CE77602B2FEBQ34184809-02F47C4A-539B-4139-A77A-4255AD876A31Q34262821-DE32EE6E-9C1C-46C1-A776-E19D4E303401Q34395565-73DA5C83-B365-485C-8D1E-34CCE37BD01FQ34503147-3F43BD80-0A37-4660-A81D-81DB925BBDFBQ34688725-A57BB5C7-0662-4D5E-AD85-D3D8B5A34B0CQ34777954-347A1487-7E4B-46EC-A17C-57BD9F7EC94BQ34829294-D139017F-2431-4EA9-BACF-458E9E451E36Q35073433-90CD1D33-CA56-431C-9B90-B909AA09AFD9Q35189515-AF48BDD2-DCCB-4544-B2D1-BCD3A058F8D0Q35537344-CB3131E7-9719-4322-964A-316215C7A479Q35670379-1EB7B7A3-2B9B-4E09-BD87-B194C491470DQ35738618-B4C5B66A-AD07-43F8-89C3-B3BB73E69F5BQ35816304-4FF5F9EE-A0A8-4554-87AF-CFAAF70FFFD1
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Molecular targets for antiepileptic drug development
@ast
Molecular targets for antiepileptic drug development
@en
Molecular targets for antiepileptic drug development
@nl
type
label
Molecular targets for antiepileptic drug development
@ast
Molecular targets for antiepileptic drug development
@en
Molecular targets for antiepileptic drug development
@nl
prefLabel
Molecular targets for antiepileptic drug development
@ast
Molecular targets for antiepileptic drug development
@en
Molecular targets for antiepileptic drug development
@nl
P2860
P1433
P1476
Molecular targets for antiepileptic drug development
@en
P2093
Brian S Meldrum
Michael A Rogawski
P2860
P2888
P356
10.1016/J.NURT.2006.11.010
P407
P577
2007-01-01T00:00:00Z
P5875
P6179
1046657870